ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Dasatinib, a tyrosine kinase inhibitor taken orally, plays a vital role in inhibiting additional active and inactive forms of ABL kinase domains, which makes this chemotherapeutic agent useful for imatinib-resistant CML [4].